Laser or Eye Drops for glaucoma: What Should Be the First Treatment Choice? For decades, the default treatment for newly diagnosed glaucoma was simple:
Start daily eye drops and continue lifelong.
However, this approach is evolving. Large clinical trials, particularly the LiGHT Trial (Laser in Glaucoma and Ocular Hypertension Trial), have shown that Selective Laser Trabeculoplasty (SLT) can safely be used as a first treatment in many patients.
Today the question is no longer:
“Should we start with eye drops?”
But rather:
“Which first treatment best protects your optic nerve over the long term?”
Because glaucoma treatment is not just about lowering pressure today.
It is about preserving vision stability for decades.
Understanding the Two First-Line Treatment Options
Most patients with open-angle glaucoma are typically offered one of two starting strategies:
Option 1: Pressure lowering eye drops
or
Option 2: Selective Laser Trabeculoplasty (SLT)
Both are valid. The best choice depends on risk profile, lifestyle, disease stage and long-term treatment sustainability.
The Case for Selective Laser Trabeculoplasty (SLT)
SLT is a gentle laser procedure that improves fluid drainage through the eye’s natural outflow pathway (trabecular meshwork).
Unlike older lasers, SLT does not cause thermal damage. It works by stimulating biological remodeling rather than destroying tissue, which allows repeat treatment in appropriate cases.
Advantages of SLT as Initial Treatment
Freedom From Daily Medication (For Many Patients)
The LiGHT trial showed that a large proportion of patients treated with SLT first were able to maintain target pressure without drops for several years.
Importantly:
This does not mean laser replaces drops forever.
But it often delays the need for medication and reduces lifetime drop burden.
This is a major advantage in a lifelong disease.
More Stable Pressure Control
Eye drops depend on perfect daily use.
Real life includes:
- Missed doses
- Travel disruption
- Cost issues
- Technique errors
- Tolerance problems
Laser works continuously and removes variability caused by human factors.
Reducing pressure fluctuation may be as important as reducing average pressure.
Eliminates Compliance Burden
Studies consistently show that many glaucoma patients unintentionally miss doses.
This is not negligence.
It is human behaviour.
SLT removes this variable and simplifies treatment.
Protection of the Ocular Surface
Long-term eye drop use, especially preserved drops, can cause:
- Chronic redness
- Burning
- Dry eye disease
- Surface inflammation
- Cosmetic eyelid changes
Starting with laser may delay or reduce this cumulative exposure.
This is increasingly recognised as an important quality-of-life factor.
When Eye Drops May Still Be the Better First Option
Despite the growing role of SLT, drops remain essential in many situations.
Good glaucoma care is individualised, not protocol driven.
Advanced Glaucoma Requiring Very Low Pressures
In advanced disease, pressure targets are often extremely low.
Laser alone may not reliably achieve these targets.
Combination therapy with drops is often necessary.
Patients Unsuitable for Laser
SLT works best in open-angle glaucoma. In India, almost half of the glaucoma patients have narrow or closed angles.
It may be less effective in:
- Some secondary glaucomas
- Inflammatory glaucomas
- Angle closure glaucomas
- Certain post-surgical situations
Clinical examination determines suitability.
Patient Preference Matters
Some patients prefer starting with medication rather than a procedure.
This is reasonable.
Treatment only works when patients are comfortable with the plan.
Cost Effectiveness: The Long-Term Perspective
Many patients initially focus on the upfront cost of SLT compared to a bottle of drops.
However glaucoma is a lifelong disease.
When considering long-term cost, factors include:
- Cost of years of medication
- Cost of multiple medications
- Cost of lubricants for drop-induced dryness
- Time burden of daily treatment
- Cost of managing intolerance
Long-term studies suggest SLT may be cost-effective over time in appropriate patients.
But cost should never be the only deciding factor.
The most important question remains:
Which treatment best protects vision stability?
SLT vs Eye Drops: A Practical Comparison
| Feature | SLT Laser | Eye Drops |
|---|---|---|
| Treatment frequency | Usually one procedure | Daily lifelong use |
| Compliance dependence | Minimal | High |
| Ocular surface impact | Minimal | May cause surface disease |
| Pressure stability | Continuous | Variable |
| Reversibility | Repeatable | Adjustable |
| Lifestyle burden | Low | Moderate to high |
Both remain important tools.
Good glaucoma care uses the right tool at the right time.
What Do Current Guidelines Suggest?
Increasingly, international glaucoma guidelines recognise SLT as a reasonable first-line treatment option for many patients with:
- Primary open angle glaucoma
- Ocular hypertension
This does not mean everyone should have laser.
It means patients should be informed of both options.
Important Question Is Not Laser vs Drops in glaucoma
It is:
Which strategy gives you the safest long-term disease control with the least treatment burden?
Because glaucoma management is a 20–30 year journey.
Small early decisions often determine long-term outcomes.
Why Laser Is Often Essential in Angle-Closure Glaucoma: LPI vs Eye Drops
While SLT and eye drops may both be reasonable first treatments in open-angle glaucoma, the situation is very different in angle-closure glaucoma.
In angle-closure disease, the problem is not just pressure, it is mechanical blockage of fluid drainage caused by the iris blocking the drainage angle.
In these cases, laser treatment called Laser Peripheral Iridotomy (LPI) is often considered essential because drops alone do not correct the underlying anatomical risk.
What Does Laser Peripheral Iridotomy (LPI) Do?
LPI creates a tiny bypass opening in the peripheral iris, allowing fluid to move more freely within the eye and reducing the risk of angle blockage.
The goal is not just pressure reduction.
The goal is preventing sudden angle closure, which can cause rapid and permanent vision loss.
This is why LPI is often considered a preventive safety procedure, not just a pressure treatment.
Why Drops Alone May Not Be Enough in Angle Closure
Eye drops can reduce pressure temporarily, but they do not address the structural cause of angle closure.
Without treating the angle anatomy, patients may remain at risk for:
- Acute angle closure attacks
- Sudden pressure spikes
- Progressive angle damage
- Late detection of progression
This is why relying only on drops in primary angle closure may leave the underlying risk untreated.
When LPI Is Typically Recommended
LPI is commonly advised in:
- Primary angle closure
- Primary angle closure glaucoma
- Fellow eye of acute angle closure
- Occludable angles at risk of closure
In these situations, laser is often part of risk prevention rather than optional therapy.
Do Patients Still Need Drops After LPI?
Sometimes yes.
LPI treats the angle mechanism but does not cure glaucoma.
Some patients may still need:
- Pressure lowering drops
- Additional laser
- Cataract surgery
- Long-term monitoring
The key concept is:
LPI reduces structural risk. Drops control pressure. You may need both .
Key Clinical Distinction
Open-angle glaucoma → Choice between SLT and drops often exists
Angle-closure disease → LPI often necessary to reduce structural risk
Understanding this difference is critical because the treatment goals are different.
Practical Takeaway
If you have been told you have narrow angles or angle-closure risk, the most important question is not:
“Can I manage with drops?”
It is:
“Has the structural risk of angle closure been adequately addressed?”
Because preventing an angle closure event is always safer than treating one after it occurs.
Frequently Asked Questions About Laser or Eye Drops for Glaucoma
Is SLT better than glaucoma eye drops?
Not universally. SLT is an excellent first option for many patients, but treatment choice depends on disease stage, pressure targets and individual factors.
Does SLT completely replace glaucoma drops?
Sometimes temporarily, sometimes partially, sometimes not. Some patients remain drop-free for years, others may still require medication.
Is SLT safe?
SLT has an excellent safety profile. Mild inflammation or redness for 1–2 days is the most common short-term effect.
How long does SLT last?
Effect duration varies. Many patients benefit for several years. Some may need repeat treatment or additional therapy.
Is SLT painful?
The procedure is usually well tolerated and takes only a few minutes. Most patients describe mild discomfort rather than pain.
Can SLT prevent glaucoma progression?
SLT lowers intraocular pressure, which is the only proven method to slow glaucoma progression.
Should everyone choose SLT first?
No. Treatment must be individualised. The best first treatment depends on clinical findings and long-term strategy.
The Real Goal of Glaucoma Treatment
Laser or Eye Drops for glaucoma: What Should Be the First Treatment Choice?
The goal is not laser.
The goal is not drops.
For us, the goal is:
Stable optic nerve health over decades.
This requires:
- Correct diagnosis
- Realistic pressure targets
- Sustainable treatment
- Regular monitoring
- Early optimisation
The best treatment is the one that patients can continue safely and consistently.
When Should You Consider Discussing SLT?
You may benefit from discussing SLT if:
- You are newly diagnosed
- You want to minimise lifetime drop use, or multiple eye drops use
- You have drop intolerance
- You struggle with daily dosing
- You want a structured long-term plan
Early decisions often shape the entire disease trajectory.
When Should You Consider a Second Opinion?
Patients often seek a second opinion when:
• Multiple glaucoma medications are being prescribed
• Laser treatment has been suggested
• Eye pressure remains uncontrolled
• Surgery is being discussed
A structured glaucoma evaluation helps determine the best long-term strategy for protecting vision. Whether it is Laser or Eye Drops for Glaucoma Treatment.
Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care
Read the research articles
This article has been written by Dr Shibal Bhartiya, a glaucoma specialist in Gurgaon known for ethical, patient-centred glaucoma care and independent glaucoma second opinions.
She has published peer-reviewed research on glaucoma laser and surgeries, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.
These peer-reviewed article discussing glaucoma treatment are benchmarks for glaucoma surgeons globally, and can be accessed on PubMed here, here, here, here, here, here, here, and here
Consultation Information
Dr Shibal Bhartiya
Glaucoma Specialist | Neuro-Ophthalmology | Second Opinions
🌐 www.drshibalbhartiya.com
📞 +91 88826 38735
